Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Piperazine derivative, preparation thereof and use thereof in medicine

A kind of pharmacy and compound technology, applied in the field of dipeptidyl peptidase IV inhibitors

Inactive Publication Date: 2009-07-01
SHANGHAI HENGRUI PHARM CO LTD
View PDF9 Cites 46 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0010] However, although several DPPIV inhibitors have been disclosed, there is still no long-acting drug, and there is still a need for DPPIV inhibitors with improved properties

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Piperazine derivative, preparation thereof and use thereof in medicine
  • Piperazine derivative, preparation thereof and use thereof in medicine
  • Piperazine derivative, preparation thereof and use thereof in medicine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0121] (R)-7-[3-amino-4-(2,4,5-trifluoro-phenyl)-butyryl]-3-trifluoromethyl-5,6,7,8-tetrahydro-imidazole Methyl [1,5-a]pyrazine-1-carboxylate hydrochloride

[0122]

[0123]

[0124] first step

[0125] 2,2-Dimethyl-5-[2-(2,4,5-trifluoro-phenyl)-acetyl]-[1,3]dioxane-4,6-dione

[0126] 2,2-Dimethyl-[1,3]dioxane-4,6-dione (5.69g, 39.5mmol) was dissolved in 400mL dichloromethane under stirring, and 2 was added under ice-cooling, 4,5-Trifluorophenylacetic acid 1a (7.15g, 37.6mmol) and p-dimethylaminopyridine (7.35g, 60.2mmol), slowly add 250mL of 1-(3-dimethylamino-propyl)-3-ethyl Base-carbodiimide hydrochloride (8.28g, 43.2mmol) dichloromethane suspension, stirred at room temperature for 36 hours, with 5% potassium bisulfate solution (250mL × 7) and saturated sodium chloride solution ( 250mL×2) Wash the reaction solution, dry it with anhydrous magnesium sulfate, filter it with suction, and concentrate the filtrate under reduced pressure to obtain the title product 2,2-di...

Embodiment 2

[0179] (R)-7-[3-amino-4-(2,4,5-trifluorophenyl)-butyryl]-3-trifluoromethyl-5,6,7,8-tetrahydro-imidazo [1,5-a]pyrazine-1-carboxylic acid (2-methylsulfonyl-ethyl)-amide hydrochloride

[0180]

[0181] first step

[0182] (R)-7-[3-tert-butoxycarbonyl-4-(2,4,5-trifluoro-phenyl)-butyryl]-3-trifluoromethyl-5,6,7,8-tetra Hydrogen-imidazo[1,5-a]pyrazine-1-carboxylic acid

[0183] (R)-7-[3-tert-butoxycarbonylamino-4-(2,4,5-trifluoro-phenyl)-butyryl]-3-trifluoromethyl-5,6,7,8 -Tetrahydro-imidazo[1,5-a]pyrazine-1-carboxylic acid methyl ester 1n (2.0g, 3.5mmol) was dissolved in 50mL methanol under stirring, added 30mL4N sodium hydroxide solution, and reacted at room temperature for 1 Hours later, follow the reaction by thin-layer chromatography, the raw materials disappeared, add 2N hydrochloric acid to adjust the pH of the reaction solution to about 3, extract the reaction solution with ethyl acetate (50mL×4), combine the organic phases, dry with anhydrous magnesium sulfate, and fi...

Embodiment 3

[0195] (R)-3-Amino-1-[1-(morpholine-4-carbonyl)-3-trifluoromethyl-5,6-dihydro-8H-imidazo[1,5-a]pyrazine- 7-yl]-4-(2,4,5-trifluorophenyl)-butan-1-one hydrochloride

[0196]

[0197] first step

[0198] (R)-[3-[1-(morpholine-4-carbonyl)-3-trifluoromethyl-5,6-dihydro-8H-imidazo[1,5-a]pyrazin-7-yl ]-3-oxo-1-(2,4,5-trifluoro-benzyl)-propyl]-tert-butyl carbamate

[0199] (R)-7-[3-tert-butoxycarbonyl-4-(2,4,5-trifluoro-phenyl)-butyryl]-3-trifluoromethyl-5,6,7,8- Tetrahydro-imidazo[1,5-a]pyrazine-1-carboxylic acid 2a (60 mg, 0.109 mmol), morpholine (19 mg, 0.218 mmol) and bis(2-oxo-3-oxazolidinyl) Phosphinoyl chloride (53.5mg, 0.218mmol) was dissolved in 5mL of dichloromethane with stirring, triethylamine (0.1mL, 0.65mmol) was added, and reacted overnight at room temperature. The reaction was tracked by thin-layer chromatography. The raw materials basically disappeared, and the reaction was evaporated to dryness. liquid, and the resulting residue was purified by silica gel colu...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to piperazidine derivatives shown in a general formula (I), a preparation method thereof, a medicine composition containing the derivatives, and use of the medicine as a therapeutic agent, in particular dipeptidyl peptidase-4 inhibitor, wherein the definitions of various substitutional groups in the general formula (I) are the same as those in the description.

Description

technical field [0001] The present invention relates to a new piperazine derivative represented by general formula (I), its preparation method and pharmaceutical composition containing the derivative, and its use as a therapeutic agent, especially as a dipeptidyl peptidase IV inhibitor use. Background technique [0002] Diabetes mellitus is a metabolic disease of multiple etiologies characterized by chronic hyperglycemia accompanied by disturbances in carbohydrate, fat and protein metabolism due to defects in insulin secretion and / or action. Diabetes is a very old disease. It is caused by the absolute or relative lack of insulin in the human body, which causes the blood glucose concentration to rise, and then a large amount of sugar is excreted from the urine, resulting in polydipsia, polyuria, polyphagia, weight loss, and dizziness. , fatigue and other symptoms. [0003] Permanent or uncontrolled hyperglycemia leads to increased morbidity and mortality. Often abnormal gl...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07D471/04A61K31/4985A61P3/10A61P3/04
CPCC07D487/04A61P3/04A61P3/10A61P5/48A61P43/00
Inventor 邓炳初杨方龙范江冯虎王阳杨韬
Owner SHANGHAI HENGRUI PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com